| Literature DB >> 31639136 |
Tiago Tomazi1,2, Gustavo Freu1, Bruna Gomes Alves1, Antonio Francisco de Souza Filho3, Marcos Bryan Heinemann3, Marcos Veiga Dos Santos1.
Abstract
A genotypic characterization of Streptococcus uberis isolated from clinical mastitis (CM) in dairy cows, and the association of Strep. uberis genotypes and antimicrobial susceptibility (AMS) was performed. A total of 89 isolates identified as Strep. uberis from 86 dairy cows with CM in 17 dairy herds of Southeastern Brazil were genotyped using random amplified polymorphic DNA (RAPD) analysis. After genotyping, two clusters (I and II) were created according to RAPD types. A commercial broth microdilution test was used to determine the susceptibility of Strep. uberis isolates to 8 antimicrobials (ampicillin, ceftiofur, cephalothin, erythromycin, penicillin, penicillin+novobiocin, pirlimycin and tetracycline). For each antimicrobial, we determined the minimal inhibitory concentrations that inhibit 50% (MIC50) and 90% (MIC90) of Strep. uberis strains. Differences in AMS among genotypic clusters were evaluated using mixed regression models. Overall, a great polymorphism (56 RAPD-types) was found among Strep. uberis isolates, although a higher genetic similarity (based on the PCR bands features) was observed within herds after genotypic clustering. No differences in AMS were observed among clusters. Strep. uberis isolated from bovine CM were resistant to most antimicrobials, with the exception of cephalothin and penicillin+novobiocin.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31639136 PMCID: PMC6805098 DOI: 10.1371/journal.pone.0223719
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Descriptive data at the herd level, absolute frequency of CM (overall and caused by Streptococcus uberis), and number of strains selected for genotyping and antimicrobial susceptibility testing.
| Herd | Housing | Herd size | Study period | CM | ||||
|---|---|---|---|---|---|---|---|---|
| Total | Cryop. | Conf. | Select. | |||||
| A | FS | 1470 (52) | Jul/14 –Jul/15 | 379 | 50 | 40 | 9 | 9 |
| B | CBPB | 184 (25) | Apr/14 –Apr/15 | 178 | 9 | 5 | 2 | 2 |
| C | PD | 68 (5) | May/14 –Apr/15 | 36 | 0 | 0 | 0 | 0 |
| D | FS | 165 (11) | Apr/14 –Apr/15 | 192 | 20 | 17 | 15 | 13 |
| E | PD | 371 (24) | Apr/14 –Apr/15 | 370 | 31 | 28 | 20 | 15 |
| F | PD | 253 (13) | Mar/14 –Apr/15 | 212 | 15 | 12 | 9 | 9 |
| G | PD | 77 (15) | Apr/14 –Nov/14 | 40 | 1 | 1 | 0 | 0 |
| H | PD | 71 (9) | Feb/15 –Jan/16 | 90 | 8 | 6 | 5 | 5 |
| I | CBPB | 167 (11) | May/14 –Apr/15 | 356 | 22 | 15 | 5 | 5 |
| J | CBPB | 120 (10) | Apr/14 –Apr/15 | 69 | 3 | 3 | 2 | 2 |
| K | FS | 313 (7) | Mar/14 –Apr/15 | 299 | 6 | 5 | 1 | 1 |
| L | PD | 194 (7) | May/14 –Apr/15 | 280 | 38 | 29 | 21 | 16 |
| M | FS | 586 (17) | Dec/14 –Dec/15 | 1208 | 33 | 12 | 3 | 3 |
| N | FS | 55 (7) | Apr/14 –Jun/15 | 76 | 4 | 4 | 1 | 1 |
| O | PD | 46 (3) | Apr/14 –Mar/15 | 44 | 4 | 4 | 3 | 3 |
| P | PD | 36 (1) | Apr/14 –Apr/15 | 68 | 4 | 4 | 2 | 2 |
| Q | CBPB | 75 (12) | May/14 –Apr/15 | 212 | 4 | 4 | 1 | 1 |
| R | PD | 22 (3) | Apr/14 –Mar/15 | 13 | 1 | 1 | 1 | 1 |
| S | PD | 55 (7) | Jun/14 –May/15 | 50 | 2 | 2 | 0 | 0 |
| T | CBPB | 46 (4) | Apr/14 –Apr/15 | 41 | 1 | 1 | 1 | 1 |
| Overall | 219 (318) | Mar/14 –Jan/16 | 4,212 | 256 | 193 | 101 | 89 | |
1Housing system of herds from which the Strep. uberis isolates were selected. FS (Free stall); CBPB (Compost Bedded Pack Barn, housing system composed by a resting area bedded with organic materials, which must be mechanically stirred on a regular basis); PD (Paddocks, housing system defined as an open area surrounded by fences or rails with or without pasture for grazing.
2Herd size—Average number of lactating cows (standard deviation in parenthesis) per herd during the study period.
3Absolute frequency (n) of clinical mastitis cases identified during the study period regardless of causing-pathogen.
4Number of clinical mastitis cases with identification of Streptococcus uberis (SU) in the bacteriological culture.
5Number of isolates cryopreserved during the study period.
6Number of isolates that were re-cultivated and confirmed as Strep. uberis using MALDI-TOF MS.
7Number of isolates selected for strain typing and AMS testing.
Dilution ranges and susceptibility breakpoints used in the antimicrobial susceptibility test of Streptococcus uberis isolated from CM.
| Antimicrobial | MIC dilution range (μg/mL) | CLSI breakpoints (μg/mL) |
|---|---|---|
| Ampicillin | 0.12–8.0 | 0.25 |
| Ceftiofur | 0.5–4.0 | 2.0 |
| Cephalothin | 2.0–16.0 | 8.0 |
| Erythromycin | 0.25–4.0 | 0.25 |
| Penicillin | 0.12–8.0 | 0.12 |
| Penicillin+novobiocin | 1.0/2.0–8.0/16.0 | 1.0/2.0 |
| Pirlimycin | 0.5–4.0 | 2.0 |
| Tetracycline | 1.0–8.0 | 2.0 |
1Susceptibility breakpoints according to the guidelines of CLSI [33]. Isolates with minimum inhibitory concentrations less than or equal to the stated breakpoints were considered as susceptible to the antimicrobial.
2Human-derived susceptibility breakpoints. As no breakpoints were available for Strep. uberis recovered from bovine mastitis in the CLSI guidelines, the susceptibility to these antimicrobials was based on breakpoints of viridans group streptococci or Streptococcus spp.
3Susceptibility breakpoints based on bovine mastitis data.
Fig 1Dendrogram of RAPD profiles of Strep. uberis strains (n = 88) recovered from cows with clinical mastitis and results of susceptibility to 8 antimicrobials (n = 83).
Three isolates were contaminated (solid line) and two had no growth during re-inoculation for AMS testing (dotted line). The interpretive criteria to categorize the RAPD-types as resistant (black boxes) or susceptible (without boxes) were based on CLSI guidelines [33].
Distribution of 88 Streptococcus uberis recovered from CM in dairy cows from 17 dairy herds according to RAPD-clusters, herd of origin, housing system, and severity score of clinical mastitis.
| Variable | Categories | I | II | RAPD-type 56 | |||
|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||
| Herd | A (n = 9) | 9 | 100 | - | - | - | - |
| B (n = 2) | 2 | 100 | - | - | - | - | |
| D (n = 12) | 12 | 100 | - | - | - | - | |
| E (n = 15) | 15 | 100 | - | - | - | - | |
| F (n = 9) | 1 | 11.1 | 8 | 88.9 | - | - | |
| H (n = 5) | - | - | 5 | 100 | - | - | |
| I (n = 5) | - | - | 4 | 80 | 1 | 20 | |
| J (n = 2) | - | - | 2 | 100 | - | - | |
| K (n = 1) | - | - | 1 | 100 | - | - | |
| L (n = 16) | - | - | 16 | 100 | - | - | |
| M (n = 3) | 3 | 100 | - | - | - | - | |
| N (n = 1) | - | - | 1 | 100 | - | - | |
| O (n = 3) | 1 | 33.3 | 2 | 66.7 | - | - | |
| P (n = 2) | 1 | 50 | 1 | 50 | - | - | |
| Q (n = 1) | - | - | 1 | 100 | - | - | |
| R (n = 1) | - | - | 1 | 100 | - | - | |
| T (n = 1) | - | - | 1 | 100 | - | - | |
| Housing | Free stall (n = 26) | 24 | 92.3 | 2 | 7.7 | - | - |
| CBPB (n = 11) | 2 | 18.2 | 8 | 72.7 | 1 | 9.1 | |
| Paddocks (n = 51) | 18 | 35.3 | 33 | 64.7 | - | - | |
| Severity | Mild (n = 50) | 23 | 46.0 | 26 | 52.0 | 1 | 2.0 |
| Moderate (n = 34) | 17 | 50.0 | 17 | 50.0 | - | - | |
| Severe (n = 3) | 3 | 100.0 | - | - | - | - | |
1Housing system of herds from which the Strep. uberis isolates were selected. CBPB (Compost Bedded Pack Barn): housing system composed by a resting area bedded with organic materials, which must be mechanically stirred on a regular basis; Paddocks: housing system defined as an open area surrounded by fences or rails with or without pasture for grazing.
2CM severity was recorded as mild, moderate and severe according to Wenz et al. [28]. Of the selected isolates (n = 88), one did not have record of CM severity, which is not described in this variable
Overall antimicrobial susceptibility of 83 strains of Streptococcus uberis isolated from clinical mastitis in 17 dairy herds from southeastern Brazil.
| Antimicrobial | Frequency (%) of isolates at each indicated MIC (μg/mL) | Res | MIC50 | MIC90 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | ||||
| Ampicillin | 18.1 | 15.7 | 51.8 | 3.6 | 0.0 | 1.2 | 1.2 | - | - | - | - | - | 8.4 | 0.5 | 4 |
| Ceftiofur | - | - | 8.5 | 4.8 | 9.6 | 41.0 | - | - | - | - | - | - | 36.1 | 4 | >4 |
| Cephalothin | - | - | - | - | 88.0 | 6.0 | 2.4 | 2.4 | - | - | - | - | 1.2 | 2 | 4 |
| Erythromycin | - | 53.1 | 8.4 | 6.0 | 3.6 | 1.2 | - | - | - | - | - | - | 27.7 | 0.25 | >4 |
| Penic+Novob. | - | - | - | 88.0 | 3.6 | 4.8 | 0.0 | - | - | - | - | - | 3.6 | 1 | 2 |
| Penicillin | 24.1 | 25.3 | 38.6 | 8.4 | 1.2 | 1.2 | 0.0 | - | - | - | - | - | 1.2 | 0.5 | 1 |
| Pirlimycin | - | - | 48.2 | 4.8 | 7.2 | 1.2 | - | - | - | - | - | - | 38.6 | 1 | >4 |
| Tetracycline | - | - | - | 7.2 | 22.9 | 13.3 | 1.2 | - | - | - | - | - | 55.4 | >8 | >8 |
1The light gray shading represents the susceptible zone, and the darker gray shading represents the resistant zone. Results were interpreted according to CLSI [33]. Interpretive criteria were based on human data (ampicillin, cephalothin, erythromycin, penicillin and tetracycline), and bovine mastitis (ceftiofur, penicillin+novobiocin and pirlimycin). The resistant category included those isolates categorized as either intermediate or resistant.
2Res: proportion of isolates that were resistant at the highest antimicrobial concentration tested.
3MIC (μg/mL) that inhibited 50% (MIC50) of the isolates.
4MIC (μg/mL) that inhibited 90% (MIC90) of the isolates.
Antimicrobial susceptibility of 82 strains of Streptococcus uberis stratified according to their genetic similarity into RAPD-clusters I (n = 40) and II (n = 42).
All isolates were recovered from cases of clinical mastitis in 17 dairy herds from southeastern Brazil.
| Antimicrobial | Cluster | Frequency (%) of isolates at each indicated MIC (μg/mL) | Res | MIC50 | MIC90 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | |||||
| Ampicillin | I | 22.5 | 7.5 | 47.5 | 7.5 | 0.0 | 0.0 | 2.5 | - | - | - | - | - | 12.5 | 0.5 | >8 |
| II | 14.3 | 23.8 | 54.8 | 0.0 | 0.0 | 2.4 | 0.0 | - | - | - | - | - | 4.7 | 0.5 | 0.5 | |
| Ceftiofur | I | - | - | 12.5 | 10.0 | 2.5 | 42.5 | - | - | - | - | - | - | 32.5 | 4 | >4 |
| II | - | - | 4.8 | 0.0 | 16.7 | 38.1 | - | - | - | - | - | - | 40.4 | 4 | >4 | |
| Cephalothin | I | - | - | - | - | 90.0 | 5.0 | 0.0 | 2.5 | - | - | - | - | 2.5 | 2 | 2 |
| II | - | - | - | - | 85.7 | 7.1 | 4.8 | 2.4 | - | - | - | - | 0.0 | 2 | 4 | |
| Erythromycin | I | - | 57.5 | 12.5 | 5.0 | 5.0 | 0.0 | - | - | - | - | - | - | 20.0 | 0.25 | >4 |
| II | - | 50.0 | 4.8 | 7.1 | 2.4 | 2.4 | - | - | - | - | - | - | 33.3 | 0.25 | >4 | |
| Penic+Novob. | I | - | - | - | 87.5 | 5.0 | 5.0 | 0.0 | - | - | - | - | - | 2.5 | 1 | 2 |
| II | - | - | - | 90.5 | 2.4 | 4.7 | 0.0 | - | - | - | - | - | 2.4 | 1 | 1 | |
| Penicillin | I | 30.0 | 15.0 | 45.0 | 5.0 | 0.0 | 2.5 | 0.0 | - | - | - | - | - | 2.5 | 0.5 | 0.5 |
| II | 19.1 | 35.7 | 33.3 | 9.5 | 2.4 | 0.0 | 0.0 | - | - | - | - | - | 0.0 | 0.25 | 1 | |
| Pirlimycin | I | - | - | 45.0 | 5.0 | 10.0 | 2.5 | - | - | - | - | - | - | 37.5 | 1 | >4 |
| II | - | - | 50.0 | 4.8 | 4.8 | 0.0 | - | - | - | - | - | - | 40.4 | 0.5 | >4 | |
| Tetracycline | I | - | - | - | 7.5 | 30.0 | 12.5 | 0.0 | - | - | - | - | - | 50.0 | 4 | >8 |
| II | - | - | - | 7.1 | 16.7 | 14.3 | 2.4 | - | - | - | - | - | 59.5 | >8 | >8 | |
1The light gray shading represents the susceptible zone, and the darker gray shading represents the resistant zone. Results were interpreted according to CLSI [33]. Interpretive criteria were based on human data (ampicillin, cephalothin, erythromycin, penicillin and tetracycline), and bovine mastitis (ceftiofur, penicillin+novobiocin and pirlimycin). The resistant category included those isolates categorized as either intermediate or resistant.
2Res: proportion of isolates that were resistant at the highest antimicrobial concentration tested.
3MIC (μg/mL) that inhibited 50% (MIC50) of the isolates.
4MIC (μg/mL) that inhibited 90% (MIC90) of the isolates.